Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Similar articles for PubMed (Select 24840269)

1.

Overcoming toxicity and side-effects of lipid-lowering therapies.

Wilkinson MJ, Laffin LJ, Davidson MH.

Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):439-52. doi: 10.1016/j.beem.2014.01.006. Epub 2014 Jan 23. Review.

PMID:
24840269
2.

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD.

Drug Saf. 2010 Mar 1;33(3):171-87. doi: 10.2165/11319380-000000000-00000. Review.

PMID:
20158283
3.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

4.

A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M.

Drugs. 2013 Jul;73(10):1025-54. doi: 10.1007/s40265-013-0072-9. Review.

PMID:
23754124
5.

Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.

Kondo Y, Hamai J, Nezu U, Shigematsu E, Kamiko K, Yamazaki S, Yoshii T, Takahashi M, Takano T, Kawasaki S, Yamada M, Yamakawa T, Terauchi Y.

Endocr J. 2014;61(4):343-51. Epub 2014 Jan 22.

6.
7.

Addressing statin adverse effects in the clinic: the 5 Ms.

Katz DH, Intwala SS, Stone NJ.

J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):533-42. doi: 10.1177/1074248414529622. Epub 2014 Apr 25. Review.

PMID:
24770611
8.

Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.

Bruckert E, Ferrières J.

Arch Cardiovasc Dis. 2014 Mar;107(3):188-200. doi: 10.1016/j.acvd.2014.01.011. Epub 2014 Mar 7.

9.

Statin intolerance: now a solved problem.

Sikka P, Kapoor S, Bindra VK, Sharma M, Vishwakarma P, Saxena KK.

J Postgrad Med. 2011 Oct-Dec;57(4):321-8. doi: 10.4103/0022-3859.90085. Review.

10.

How well tolerated are lipid-lowering drugs?

Tomlinson B, Chan P, Lan W.

Drugs Aging. 2001;18(9):665-83. Review.

PMID:
11599634
11.

Managing statin-induced muscle toxicity in a lipid clinic.

Blaier O, Lishner M, Elis A.

J Clin Pharm Ther. 2011 Jun;36(3):336-41. doi: 10.1111/j.1365-2710.2011.01254.x. Epub 2011 Mar 18.

PMID:
21414023
12.

Statin safety: an overview and assessment of the data--2005.

Bays H.

Am J Cardiol. 2006 Apr 17;97(8A):6C-26C. Epub 2006 Feb 8. Review.

PMID:
16581330
13.

[Statin myopathy--rarity or reality?].

Pella D.

Vnitr Lek. 2010 Sep;56(9 Suppl):972-6. Review. Slovak.

PMID:
21137170
14.
15.

Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.

Geng Q, Ren J, Chen H, Lee C, Liang W.

Curr Med Res Opin. 2013 Mar;29(3):181-8. doi: 10.1185/03007995.2013.766592. Epub 2013 Feb 6.

PMID:
23323878
16.

Adverse effects of statins - mechanisms and consequences.

Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A.

Curr Drug Saf. 2009 Sep;4(3):209-28. Epub 2009 Sep 1. Review.

PMID:
19534648
17.

Statin-induced myopathy: a review and update.

Abd TT, Jacobson TA.

Expert Opin Drug Saf. 2011 May;10(3):373-87. doi: 10.1517/14740338.2011.540568. Epub 2011 Feb 23. Review.

PMID:
21342078
18.

[Impact of lipid lowering therapy on liver function].

Paragh G, Fülöp P.

Orv Hetil. 2009 Jun 28;150(26):1205-12. doi: 10.1556/OH.2009.28629. Review. Hungarian.

PMID:
19546077
19.

Current overview of statin-induced myopathy.

Rosenson RS.

Am J Med. 2004 Mar 15;116(6):408-16. Review.

PMID:
15006590
20.

Managing the underestimated risk of statin-associated myopathy.

Rallidis LS, Fountoulaki K, Anastasiou-Nana M.

Int J Cardiol. 2012 Sep 6;159(3):169-76. doi: 10.1016/j.ijcard.2011.07.048. Epub 2011 Aug 2. Review.

PMID:
21813193
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk